MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
June 27, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Provides Development Progress Updates on MRT-2359 and MRT-6160
arvinas_logoART_lg.jpg
Arvinas Appoints Andrew Saik as Chief Financial Officer and Treasurer
June 24, 2024 16:37 ET | Arvinas Inc.
- Awards Mr. Saik an Inducement Grant in accordance with Nasdaq Listing Rule 5635(c)(4) - NEW HAVEN, Conn., June 24, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ: ARVN), a clinical-stage...
arvinas_logoART_lg.jpg
Arvinas Announces Presentations for Two of its PROTAC® Investigational Programs Targeting BCL6 and LRRK2
June 21, 2024 07:00 ET | Arvinas Inc.
– Preclinical data for ARV-393 presented at the European Hematology Association 2024 Annual Congress showed anti-tumor activity in models of B-cell lymphoma –  – Preclinical data presented at the...
Ian Taylor, Ph.D.
Arvinas Announces Promotions of Ian Taylor, Ph.D. to President of Research and Development and Angela Cacace, Ph.D. to Chief Scientific Officer
June 17, 2024 07:00 ET | Arvinas Inc.
NEW HAVEN, Conn., June 17, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
June 14, 2024 08:45 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics Presents Preclinical Data at EULAR 2024 Demonstrating Therapeutic Potential of MRT-6160 for the Treatment of Rheumatoid Arthritis
arvinas_logoART_lg.jpg
Arvinas to Participate in Upcoming Investor Conferences
June 03, 2024 16:30 ET | Arvinas Inc.
NEW HAVEN, Conn., June 03, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today...
MRTX_Logo_PrimaryBlue_4CP.jpg
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
May 30, 2024 07:00 ET | Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics to Present at the Jefferies Global Healthcare Conference
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Congress
May 23, 2024 17:00 ET | Arvinas Inc.
NEW HAVEN, Conn., May 23, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two abstracts, including one for ARV-766 in prostate cancer and one for TACTIVE-K, a Phase 1b/2...
arvinas_logoART_lg.jpg
Arvinas and Pfizer Announce Updated Clinical Data from Phase 1b Trial of Vepdegestrant in Combination with Palbociclib (IBRANCE®)
May 16, 2024 06:00 ET | Arvinas Inc.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in...
arvinas_logoART_lg.jpg
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
May 09, 2024 16:42 ET | Arvinas Inc.
NEW HAVEN, Conn., May 09, 2024 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) today announced that two posters, including updated clinical trial data, for vepdegestrant will be presented at the...